Jabre Capital Partners’s Teva Pharmaceuticals TEVA Stock Holding History

Jabre Capital Partners’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-115,000	Closed	-$5.29M	–	121
2016 Q3	$5.29M	Buy	+115,000	New	+$6M	0.72%	41
2016 Q2	–	Sell	-60,000	Closed	-$2.66M	–	99
2016 Q1	$2.66M	Buy	+60,000	New	+$3.52M	0.42%	71
2015 Q3	–	Sell	-50,000	Closed	-$2.96M	–	97
2015 Q2	$2.96M	Buy	+50,000	New	+$3.08M	0.29%	73

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Nordea Investment Management Stockholm, Sweden $107B AUM 24.58% 1-Year Est. Return

Jabre Capital Partners's TEVA Position: Q4 2016 in Review

Jabre Capital Partners sold out of Teva Pharmaceuticals (TEVA) in Q4 2016, closing a stake of 115,000 shares — an estimated $5.29M sold.

Jabre Capital Partners first reported a position in TEVA in Q2 2015 and held it in 3 quarters. The position peaked at $5.29M in Q3 2016. 737 funds tracked by Wall St. Rank hold TEVA as of Q4 2016.

Jabre Capital Partners reported no remaining Teva Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
Jabre Capital Partners sold 115,000 Teva Pharmaceuticals shares in Q4 2016, an estimated $5.29M.
Jabre Capital Partners first reported a position in Teva Pharmaceuticals in Q2 2015 and held it in 3 quarters.
Jabre Capital Partners's Teva Pharmaceuticals position peaked at $5.29M in Q3 2016.
737 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2016.

Based on Jabre Capital Partners's 13F filing for Q4 2016, filed 14 Feb 2017.